$20.08
-1.2%Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Strong working capital position provides significant operational flexibility and financial cushion.
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
ALMS • NASDAQ
| Alumis Inc. Common Stock Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
ASSETS | ||||
CURRENT ASSETS | ||||
89.7M | 169.5M | 46M | 25.6M | |
218.8M | 118.7M | 3M | 67.3M | |
308.5M | 288.3M | 49M | 92.9M | |
2.1M | 1.8M | 722K | 500K | |
0.0 | 1.8M | 722K | 500K | |
2.1M | 0.0 | 0.0 | 0.0 | |
0.0 | 15.4M | 3.5M | 9M | |
7.6M | 762K | 208K | 206K | |
318.2M | 306.2M | 53.4M | 102.6M | |
NON-CURRENT ASSETS | ||||
35.2M | 33.7M | 35.2M | 4.5M | |
51M | 0.0 | 0.0 | 0.0 | |
51M | 0.0 | 0.0 | 0.0 | |
7.6M | 1.1M | 1M | 1.1M | |
93.7M | 34.8M | 36.3M | 5.6M | |
411.9M | 341M | 89.6M | 108.2M | |
LIABILITIES | ||||
CURRENT LIABILITIES | ||||
10.1M | 9.6M | 1.1M | 1.7M | |
10.1M | 9.6M | 1.1M | 1.7M | |
0.0 | 32M | 12.4M | 6.7M | |
4.7M | 0.0 | 0.0 | 0.0 | |
0.0 | 1.6M | 1.7M | 1.3M | |
1.5M | 0.0 | 0.0 | 0.0 | |
57.1M | 7.8M | 5.6M | 3.6M | |
73.3M | 50.9M | 20.9M | 13.4M | |
NON-CURRENT LIABILITIES | ||||
2.6M | 0.0 | 0.0 | 0.0 | |
2.1M | 0.0 | 0.0 | 0.0 | |
330K | 814K | 377.1M | 289.6M | |
37.3M | 30M | 408M | 290.1M | |
32.2M | 30.7M | 32.6M | 1.8M | |
110.6M | 80.9M | 428.9M | 303.4M | |
SHAREHOLDERS' EQUITY | ||||
9K | 4K | 1K | 1K | |
1.2B | 918.6M | 25.1M | 14.2M | |
-901.9M | -658.6M | -364.3M | -209.3M | |
188K | 40K | 2K | -127K | |
301.3M | 260.1M | -339.3M | -195.2M | |
301.3M | 260.1M | -339.3M | -195.2M | |
SUMMARY | ||||
411.9M | 341M | 89.6M | 108.2M | |
218.8M | 118.7M | 3M | 67.3M | |
36.9M | 30.7M | 32.6M | 1.8M | |
-52.8M | -138.8M | -13.4M | -23.8M | |
104,070,402 | 104,070,402 | 104,070,402 | 104,070,402 |
ALMS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | May 18, 2026 | June 30, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 28, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 06, 2026 | January 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 02, 2026 | January 02, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 |
Continue your ALMS research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.